Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

Item
http://www.wikidata.org/entity/Q33762340
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.Personalized medicine for the management of benign prostatic hyperplasiaSurgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor networkMechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.Health-related quality-of-life findings for the prostate cancer prevention trialAge and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Future directions in the prevention of prostate cancer.Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction.Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: New therapeutic indication?
P2860

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

Item
http://www.wikidata.org/entity/Q33762340
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@ast
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@en
type
label
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@ast
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@en
prefLabel
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@ast
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia
@en
P2093
P2860
P304
P31
P356
10.1016/J.EURURO.2012.03.007
P407
P433
P478
P50
P577
P5875
P698
P932